Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

@article{Ross2009GeneticVI,
  title={Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy},
  author={Colin J D Ross and Hagit Katzov-Eckert and Marie-Pierre Dub{\'e} and Beth Brooks and S Rod Rassekh and Amina Barhdadi and Yassamin Feroz-Zada and Henk Visscher and Andrew M. K. Brown and Michael J Rieder and Paul C. Rogers and Michael S. Phillips and Bruce C. Carleton and Michael R. Hayden},
  journal={Nature Genetics},
  year={2009},
  volume={41},
  pages={1345-1349}
}
Cisplatin is a widely used and effective chemotherapeutic agent, although its use is restricted by the high incidence of irreversible ototoxicity associated with it. In children, cisplatin ototoxicity is a serious and pervasive problem, affecting more than 60% of those receiving cisplatin and compromising language and cognitive development. Candidate gene studies have previously reported associations of cisplatin ototoxicity with genetic variants in the genes encoding glutathione S-transferases… 
Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study
TLDR
A polygenic model is proposed, which takes into account multiple interacting genes of the cisplatin pathway that together confer an increased risk of ototoxicity.
Genetic variation in Otos is associated with cisplatin-induced ototoxicity.
TLDR
A potentially protective role for the variant G alleles of SNPs rs77124181 and rs2291767 in Otos against the development of cisplatin-induced ototoxicity is indicated.
Economic impact of a genetic test for cisplatin-induced ototoxicity
TLDR
It is estimated that administering this genetic test to every pediatric cancer patient for whom cisplatin is first-line therapy could potentially avoid an average of $71 168 in societal costs per tested patient, which translates into a potential present value savings of over $2.4 million annually in British Columbia and over $19.6 million in Canada.
TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity
TLDR
An association between the ACYP2 polymorphism and cisplatin-induced ototoxicity, but not with the TPMT and COMT is shown.
Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF)
TLDR
This is the first study to suggest that germline genetic variants of ARVCF may affect TGCT outcome and the result of this study is hypothesis generating and should be validated in future studies.
Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study
TLDR
Genetic factors identified as part of this pan-European project, PanCareLIFE, may contribute to future risk prediction models that can be incorporated in future clinical trials of platinum-based therapies for cancer and may help with the development of prevention strategies.
Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1
TLDR
It was found that there was no relationship between DNA repair gene polymorphisms and hearing toxicity of cisplatin, and the polymorphism in DNA repair genes was studied using primer and probes in Light Cycler device after DNA isolation was carried out with PCR technique.
Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients.
...
...

References

SHOWING 1-10 OF 42 REFERENCES
Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin
TLDR
No association between cisplatin-induced ototoxicity and any allele of rs4668123 is found but a higher frequency of the A-allele of rs2075252 is observed in the group with hearing impairment than in the groups with normal hearing after cisPlatin therapy, indicating that SNPs at the megalin gene might impact the individual susceptibility against cisplin-induced Ototoxicity.
Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
TLDR
Traditional reporting of toxicity data (CTCAE) has under-reported ototoxicity and minimized the significance of hearing loss in children, especially in patients younger than 5 years.
Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
TLDR
The presence of both alleles of 105Val-GSTP1 offered protection against cisplatin-induced hearing impairment, and two genotype patterns with good and poor protection against bisphosphorus-induced ototoxicity were identified.
Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin
TLDR
The aim of this study was to determine whether the polymorphisms in five GST genes affect the individual risk of ototoxicity by cisplatin and to find a protective effect for the GSTM3*B allele, which appears to be critical in protection against oxidative stress.
Ototoxicity From Cisplatin Therapy in Childhood Cancer
TLDR
It is demonstrated that DPOAE should be used for screening of hearing abnormalities and, once hearing damage is identified, patients require expert audiologic pediatric evaluation and (where indicated) use of hearing aids and/or speech therapy.
Genotypic Approaches to Therapy in Children
TLDR
The Genetic Approaches to Therapy in Children (GATC) project is a national project established in Canada to identify novel predictive genomic markers for severe ADRs in children and applies genomics‐based technologies to identify ADR‐associated genetic markers with the goal of preventing serious ADR in susceptible children.
Risk factors for ototoxicity due to cisplatin.
TLDR
Patients in poor general medical condition with low levels of red blood cells or serum proteins are at increased risk for development of hearing loss from cisplatin chemotherapy, and it is recommended that hearing be tested before chemotherapy begins and after the first course of cisPlatin.
Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer
TLDR
Race/ethnicity was independently correlated with the incidence of nephrotoxicity; African-American subjects were more likely to develop neph rotoxicity independent of the influence of these concurrent medications.
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
TLDR
It is concluded that genetic polymorphism in TPMT is an important determinant of mercaptopurine toxicity, even among patients who are heterozygous for this trait.
...
...